GeneDx Holdings Corp. (NASDAQ:WGS) Shares Bought by Thompson Davis & CO. Inc.

Thompson Davis & CO. Inc. raised its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 44.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 21,130 shares of the company’s stock after purchasing an additional 6,530 shares during the period. GeneDx accounts for about 1.0% of Thompson Davis & CO. Inc.’s holdings, making the stock its 8th biggest position. Thompson Davis & CO. Inc.’s holdings in GeneDx were worth $1,624,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of WGS. Barclays PLC lifted its stake in shares of GeneDx by 346.3% in the 3rd quarter. Barclays PLC now owns 18,921 shares of the company’s stock valued at $803,000 after purchasing an additional 14,681 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of GeneDx in the 3rd quarter valued at $325,000. Charles Schwab Investment Management Inc. lifted its stake in shares of GeneDx by 304.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after purchasing an additional 110,666 shares during the last quarter. Chartwell Investment Partners LLC acquired a new stake in shares of GeneDx in the 3rd quarter valued at $1,722,000. Finally, Lisanti Capital Growth LLC acquired a new stake in shares of GeneDx in the 3rd quarter valued at $1,554,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Insider Transactions at GeneDx

In other news, CFO Kevin Feeley sold 1,137 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $76.37, for a total transaction of $86,832.69. Following the transaction, the chief financial officer now owns 24,731 shares in the company, valued at approximately $1,888,706.47. The trade was a 4.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Katherine Stueland sold 10,501 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $76.75, for a total transaction of $805,951.75. Following the transaction, the chief executive officer now owns 71,146 shares in the company, valued at approximately $5,460,455.50. The trade was a 12.86 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 127,584 shares of company stock worth $11,336,520. 27.30% of the stock is currently owned by company insiders.

GeneDx Stock Performance

Shares of WGS opened at $95.83 on Friday. The company has a market capitalization of $2.63 billion, a PE ratio of -48.89 and a beta of 2.01. GeneDx Holdings Corp. has a one year low of $6.79 and a one year high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company’s fifty day moving average price is $79.05 and its 200 day moving average price is $62.88.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.04 by $0.66. The firm had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, analysts expect that GeneDx Holdings Corp. will post 0.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on WGS shares. The Goldman Sachs Group lifted their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday. Wells Fargo & Company lifted their price objective on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. TD Cowen lifted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Finally, Craig Hallum lifted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.